Gönül ÇATLI, Ayhan ABACI, Ahmet ANIK, Tolga ÜNÜVAR, İbrahim Mert ERBAŞ, Bayram ÖZHAN, Selda Ayça ALTINCIK

Does fludrocortisone treatment cause hypomagnesemia in children with primary adrenal insufficiency?

Background/aim: Aldosterone is a mineralocorticoid that secreted from adrenal glands and a known factor to increase magnesium excretion by direct and indirect effects on renal tubular cells. Although the frequency of hypomagnesemia was found to be approximately 5% in adult studies, there is no study in the literature investigating the frequency of hypomagnesemia in children by using fludrocortisone, which has a mineralocorticoid activity. Materials and methods: A multi-center retrospective study was conducted, including children who were under fludrocortisone treatment for primary adrenal insufficiency and applied to participant pediatric endocrinology outpatient clinics. Results: Forty-three patients (58.1% male, 41.9% prepubertal) included in the study, whose median age was 9.18 (0.61-19) years, and the most common diagnosis among the patients was a salt-wasting form of congenital adrenal hyperplasia (67.4%). Mean serum magnesium level was 2.05 (±0.13) mg/dL, and hypomagnesemia was not observed in any of the patients treated with fludrocortisone. None of the patients had increased urinary excretion of magnesium. Conclusion: Unlike the studies performed in adults, we could not find any evidence of magnesium wasting effect of fludrocortisone treatment with normal or even high doses in children and adolescents.Key words: Mineralocorticoids, magnesium, magnesuria, pediatrics, primary adrenal insufficiency

PDF

___

1. Agus ZS. Mechanisms and causes of hypomagnesemia. Current Opinion in Nephrology and Hypertension 2016; 25 (4): 301- 307. doi: 10.1097/MNH.0000000000000238
2. Quamme GA. Renal magnesium handling: new insights in understanding old problems. Kidney International 1997; 52 (5): 1180-1195. doi: 10.1038/ki.1997.443
3. Viering DHHM, de Baaij JHF, Walsh SB, Kleta R, Bockenhauer D. Genetic causes of hypomagnesemia, a clinical overview. Pediatric Nephrology 2017; 32 (7): 1123-1135. doi: 10.1007/ s00467-016-3416-3
4. Valinsky WC, Jolly A, Miquel P, Touyz RM, Shrier A. Aldosterone upregulates transient receptor potential melastatin 7 (TRPM7). Journal of Biological Chemistry 2016; 291 (38): 20163-20172. doi: 10.1042/CS20171525
5. Horton R, Biglieri EG. Effect of aldosterone on the metabolism of magnesium. Journal of Clinical Endocrinology and Metabolism 1962; 22: 1187-1192. doi: 10.1210/jcem-22-12- 1187
6. Monteilh-Zoller MK, Hermosura MC, Nadler MJ, Scharenberg AM, Penner R et al. TRPM7 provides an ion channel mechanism for cellular entry of trace metal ions. Journal of General Physiology 2003; 121 (1): 49-60. doi: 10.1085/ jgp.20028740
7. Runnels LW, Yue L, Clapham, DE. TRP-PLIK, a bifunctional protein with kinase and ion channel activities. Science 2001; 291 (5506): 1043-1047. doi: 10.1126/science.1058519
8. Nadler MJ, Hermosura MC, Inabe K, Perraud AL, Zhu Q et al. LTRPC7 is a Mg.ATP-regulated divalent cation channel required for cell viability. Nature 2001; 411 (6837): 590-595. doi: 10.1038/35079092
9. Delva P, Pastori C, Degan M, Montesi G, Brazzarola P et al. Intralymphocyte free magnesium in patients with primary aldosteronism: aldosterone and lymphocyte magnesium homeostasis. Hypertension 2000; 35 (1): 113-117. doi: 10.1161/01.hyp.35.1.113
10. Matsuoka H. Aldosterone and magnesium. Clinical Calcium 2005; 15 (2): 187-191 (in Japanese).
11. Maccabee-Ryaboy N, Thomas W, Kyllo J, Lteif A, Petryk A et al. Hypertension in children with congenital adrenal hyperplasia. Clinical endocrinology (Oxford) 2016; 85 (4): 528-534. doi: 10.1111/cen.13086
12. Bonfig W, Schwarz HP. Blood pressure, fludrocortisone dose and plasma renin activity in children with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency followed from birth to 4 years of age. Clinical Endocrinology (Oxford) 2014; 81 (6): 871-875. doi: 10.1111/cen.12498
13. Grijalva CG, Biaggioni I, Griffin MR, Shibao CA. Fludrocortisone is associated with a higher risk of all-cause hospitalizations compared with midodrine in patients with orthostatic hypotension. Journal of the American Heart Association 2017; 6 (10): e006848. doi: 10.1161/ JAHA.117.006848
14. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Archives of Disease in Childhood 1976; 51: 170- 179. doi: 10.1136/adc.51.3.170
15. Rosenfield RL, Qin K. Adrenocortical disorders in ınfancy and childhood. In: Kenneth LB (editor). Principles and Practice of Endocrinology and Metabolism. 3rd ed. Philadelphia, PA, USA; 2001. pp. 807.
16. Demir K, Konakçı E, Özkaya G, Kasap Demir B, Özen S et al. New features for Child Metrics: further growth references and blood pressure calculations. Journal of Clinical Research in Pediatric Endocrinology 2020; 12 (2): 125-129. doi: 10.4274/ jcrpe.galenos.2019.2019.0127
17. Neyzi O, Bundak R, Gökçay G, Günöz H, Furman A et al. Reference values for weight, height, head circumference, and body mass index in Turkish children. Journal of Clinical Research in Pediatric Endocrinology 2015; 7 (4): 280-293. doi: 10.4274/jcrpe.2183
18. Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE et al. Subcommittee on screening and management of high blood pressure in children. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 2017; 140 (3): e20171904. doi: 10.1542/peds.2017-1904
19. Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist. 2nd ed. Stanford, CA, USA: Stanford University Press; 1959.
20. Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A et al. Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2016; 101 (2): 364-389. doi: 10.1210/jc.2015-1710
21. Hindmarsh PC. Management of the child with congenital adrenal hyperplasia. Best Practice & Research: Clinical Endocrinology & Metabolism 2009; 23 (2): 193-208. doi: 10.1016/j.beem.2008.10.010
22. Güran T. Latest insights on the etiology and management of primary adrenal insufficiency in children. Journal of Clinical Research in Pediatric Endocrinology 2017; 9 (Suppl 2): 9-22. doi: 10.4274/jcrpe.2017.S002
23. Wijaya M, Huamei M, Jun Z, Du M, Li Y, Chen Q et al. Etiology of primary adrenal insufficiency in children: a 29-year singlecenter experience. Journal of Pediatric Endocrinology and Metabolism 2019; 32 (6): 615-622. doi: 10.1515/jpem-2018- 0445
24. Perry R, Kecha O, Paquette J, Huot C, Van Vliet G et al. Primary adrenal insufficiency in children: twenty years experience at the Sainte-Justine Hospital, Montreal. Journal of Clinical Endocrinology and Metabolism 2005; 90 (6): 3243-3250. doi: 10.1210/jc.2004-0016
25. Kirkgoz T, Guran T. Primary adrenal insufficiency in children: diagnosis and management. Best Practice & Research: Clinical Endocrinology & Metabolism 2018; 32 (4): 397-424. doi: 10.1016/j.beem.2018.05.010
26. Bonfig W, Pozza SBD, Schmidt H, Pagel P, Knorr D et al. Hydrocortisone dosing during puberty in patients with classical congenital adrenal hyperplasia: An evidence-based recommendation. Journal of Clinical Endocrinology and Metabolism 2009; 94 (10): 3882-3888. doi: 10.1210/jc.2009-0942
27. Shulman DI, Palmert MR, Kemp SF, Lawson Wilkins Drug and Therapeutics Committee. Adrenal insufficiency: still a cause of morbidity and death in childhood. Pediatrics 2007; 119 (2): 484- 494. doi: 10.1542/peds.2006-1612
28. Esposito D, Pasquali D, Johannsson G. Primary adrenal insufficiency: managing mineralocorticoid replacement therapy. Journal of Clinical Endocrinology and Metabolism 2018; 103 (2): 376-387. doi: 10.1210/jc.2017-01928
29. Romani AM. Cellular magnesium homeostasis. Archives of Biochemistry and Biophysics 2011; 512 (1): 1-23. doi: 10.1016/j.abb.2011.05.010
30. de Baaij JH, Hoenderop JG, Bindels RJ. Magnesium in man: implications for health and disease. Physiological Reviews 2015; 95 (1): 1-46. doi: 10.1152/physrev.00012.2014
31. Glaudemans B, van der Wijst J, Scola RH, Lorenzoni PJ, Heister A et al. A missense mutation in the Kv1.1 voltage-gated potassium channel-encoding gene KCNA1 is linked to human autosomal dominant hypomagnesemia. Journal of Clinical Investigation 2009; 119 (4): 936-942. doi: 10.1172/JCI36948
32. Yogi A, Callera GE, O’Connor S, Antunes TT, Valinsky W et al. Aldosterone signaling through transient receptor potential melastatin 7 cation channel (TRPM7) and its α-kinase domain. Cellular Signalling 2013; 25 (11): 2163-2175. doi: 10.1016/j. cellsig.2013.07.002
33. Rousseau G, Baxter JD, Funder JW, Edelman IS, Tomkins GM. Glucocorticoid and mineralocorticoid receptors for aldosterone. Journal of Steroid Biochemistry and Molecular Biology 1972; 3 (2): 219-227. doi: 10.1016/0022-4731(72)90053-2
34. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987; 237 (4812): 268-275. doi: 10.1126/science.3037703
35. Jeong Y, Chaupin DF, Matsushita K, Yamakuchi M, Cameron SJ et al. Aldosterone activates endothelial exocytosis. Proceedings of the National Academy of Sciences of the United States of America 2009; 106 (10): 3782-3787. doi: 10.1073/ pnas.0804037106
36. McEneaney V, Harvey BJ, Thomas W. Aldosterone rapidly activates protein kinase D via a mineralocorticoid receptor/ EGFR transactivation pathway in the M1 kidney CCD cell line. Journal of Steroid Biochemistry and Molecular Biology 2007; 107 (3-5): 180-190. doi: 10.1016/j.jsbmb.2007.03.043
37. Gros R, Ding Q, Sklar LA, Prossnitz EE, Arterburn JB et al. GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension 2011; 57 (3): 442-451. doi:10.1161/ HYPERTENSIONAHA.110.161653
38. Christ M, Meyer C, Sippel K, Wehling M. Rapid aldosterone signaling in vascular smooth muscle cells: involvement of phospholipase C, diacylglycerol and protein kinase C α. Biochemical and Biophysical Research Communications 1995; 213 (1): 123-129. doi: 10.1006/bbrc.1995.2106
39. Christ M, Eisen C, Aktas J, Theisen K, Wehling M. The inositol-1,4,5-trisphosphate system is involved in rapid effects of aldosterone in human mononuclear leukocytes. Journal of Clinical Endocrinology and Metabolism 1993; 77 (6): 1452- 1457. doi: 10.1210/jcem.77.6.8263127
40. Sontia B, Montezano AC, Paravicini T, Tabet F, Touyz RM. Downregulation of renal TRPM7 and increased inflammation and fibrosis in aldosterone-infused mice: effects of magnesium. Hypertension 2008; 51 (4): 915-921. doi: 10.1161/ HYPERTENSIONAHA.107.100339
41. Massry SG, Coburn JW, Chapman LW, Kleeman CR. The acute effect of adrenal steroids on the interrelationship between the renal excretion of sodium, calcium and magnesium. Journal of Laboratory and Clinical Medicine 1967; 70 (4): 563-570.
42. Ichihara A, Suzuki H, Saruta T. Effects of magnesium on the renin-angiotensin-aldosterone system in human subjects. Journal of Laboratory and Clinical Medicine 1993; 122 (4): 432-440.
43. Resnick LM, Laragh JH. Calcium metabolism and parathyroid function in primary aldosteronism. The American Journal of Medicine 1985; 78 (3): 385-390. doi: 10.1016/0002- 9343(85)90328-6
44. Berthelot A, Pernot F, Gairard A. Influence of the thyroid and parathyroid glands on magnesium metabolism during mineralocorticoid treatment (DOCA + NaCl) in the rat. Annals of Nutrition and Metabolism 1983; 27 (4): 349-354. doi: 10.1159/000176700
45. O’Connor H, Proske D, Batool A, Shakher J. A novel case of hypomagnesaemia secondary to fludrocortisone. In: Proceedings of the 18th European Congress of Endocrinology; Munich, Germany. EP275. doi: 10.1530/endoabs.41.EP275
46. Kobayashi A, Igarashi Y. Serum magnesium level in the saltlosing type of congenital adrenal hyperplasia. Archives of Disease in Childhood 1968; 43 (228): 223-228. doi: 10.1136/ adc.43.228.223